Efficacy of CD40 Agonists Is Mediated by Distinct CDC Subsets and Subverted by Suppressive Macrophages

Overview

Journal Cancer Res

Specialty Oncology

Date 2022 Aug 18

PMID 35979635

Authors

Aleksandar Murgaski

Mate Kiss

Helena Van Damme

Daliya Kancheva

Isaure Vanmeerbeek

Jiri Keirsse

Eva Hadadi

Jan Brughmans

Sana M Arnouk

Ahmed E I Hamouda

Ayla Debraekeleer

Victor Bosteels

Yvon Elkrim

Louis Boon

Sabine Hoves

Niels Vandamme

Sofie Deschoemaeker

Sophie Janssens

Abhishek D Garg

Greetje Vande Velde

Martina Schmittnaegel

Carola H Ries

Damya Laoui

Affiliations

Soon will be listed here.

Abstract

Significance: This work highlights the temporal roles of different dendritic cell subsets in promoting CD8+ T-cell-driven responses to CD40 agonist therapy in cancer.

Citing Articles

Mapping intratumoral myeloid-T cell interactomes at single-cell resolution reveals targets for overcoming checkpoint inhibitor resistance.

Bridges K, Pizzurro G, Baysoy A, Baskaran J, Xu Z, Mathew V bioRxiv. 2024; .

PMID: 39554094 PMC: 11565996. DOI: 10.1101/2024.10.28.620093.

A single-cell transcriptomic map of the murine and human multiple myeloma immune microenvironment across disease stages.

Verheye E, Kancheva D, Satilmis H, Vandewalle N, Fan R, Bardet P J Hematol Oncol. 2024; 17(1):107.

PMID: 39511632 PMC: 11546219. DOI: 10.1186/s13045-024-01629-3.

Targeting conserved TIM3VISTA tumor-associated macrophages overcomes resistance to cancer immunotherapy.

Vanmeerbeek I, Naulaerts S, Sprooten J, Laureano R, Govaerts J, Trotta R Sci Adv. 2024; 10(29):eadm8660.

PMID: 39028818 PMC: 11259173. DOI: 10.1126/sciadv.adm8660.

Neoantigen Identification and Dendritic Cell-Based Vaccines for Lung Cancer Immunotherapy.

Kumari K, Singh A, Chaudhary A, Singh R, Shanker A, Kumar V Vaccines (Basel). 2024; 12(5).

PMID: 38793749 PMC: 11125796. DOI: 10.3390/vaccines12050498.

A spatial architecture-embedding HLA signature to predict clinical response to immunotherapy in renal cell carcinoma.

Kinget L, Naulaerts S, Govaerts J, Vanmeerbeek I, Sprooten J, Laureano R Nat Med. 2024; 30(6):1667-1679.

PMID: 38773341 DOI: 10.1038/s41591-024-02978-9.

References

Kashyap A, Schmittnaegel M, Rigamonti N, Pais-Ferreira D, Mueller P, Buchi M . Optimized antiangiogenic reprogramming of the tumor microenvironment potentiates CD40 immunotherapy. Proc Natl Acad Sci U S A. 2020; 117(1):541-551. PMC: 6955310. DOI: 10.1073/pnas.1902145116. View

Johnson P, Challis R, Chowdhury F, Gao Y, Harvey M, Geldart T . Clinical and biological effects of an agonist anti-CD40 antibody: a Cancer Research UK phase I study. Clin Cancer Res. 2015; 21(6):1321-8. DOI: 10.1158/1078-0432.CCR-14-2355. View

Kurtulus S, Madi A, Escobar G, Klapholz M, Nyman J, Christian E . Checkpoint Blockade Immunotherapy Induces Dynamic Changes in PD-1CD8 Tumor-Infiltrating T Cells. Immunity. 2019; 50(1):181-194.e6. PMC: 6336113. DOI: 10.1016/j.immuni.2018.11.014. View

Velde G, Poelmans J, De Langhe E, Hillen A, Vanoirbeek J, Himmelreich U . Longitudinal micro-CT provides biomarkers of lung disease that can be used to assess the effect of therapy in preclinical mouse models, and reveal compensatory changes in lung volume. Dis Model Mech. 2015; 9(1):91-8. PMC: 4728330. DOI: 10.1242/dmm.020321. View

Van Overmeire E, Stijlemans B, Heymann F, Keirsse J, Morias Y, Elkrim Y . M-CSF and GM-CSF Receptor Signaling Differentially Regulate Monocyte Maturation and Macrophage Polarization in the Tumor Microenvironment. Cancer Res. 2015; 76(1):35-42. DOI: 10.1158/0008-5472.CAN-15-0869. View

Schoenberger S, Toes R, van der Voort E, Offringa R, Melief C . T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature. 1998; 393(6684):480-3. DOI: 10.1038/31002. View

Simoni Y, Becht E, Fehlings M, Loh C, Koo S, Teng K . Bystander CD8 T cells are abundant and phenotypically distinct in human tumour infiltrates. Nature. 2018; 557(7706):575-579. DOI: 10.1038/s41586-018-0130-2. View

Street K, Risso D, Fletcher R, Das D, Ngai J, Yosef N . Slingshot: cell lineage and pseudotime inference for single-cell transcriptomics. BMC Genomics. 2018; 19(1):477. PMC: 6007078. DOI: 10.1186/s12864-018-4772-0. View

Kiss M, Vande Walle L, Saavedra P, Lebegge E, Van Damme H, Murgaski A . IL1β Promotes Immune Suppression in the Tumor Microenvironment Independent of the Inflammasome and Gasdermin D. Cancer Immunol Res. 2020; 9(3):309-323. DOI: 10.1158/2326-6066.CIR-20-0431. View

10.

OHara M, OReilly E, Varadhachary G, Wolff R, Wainberg Z, Ko A . CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study. Lancet Oncol. 2021; 22(1):118-131. DOI: 10.1016/S1470-2045(20)30532-5. View

11.

Suntharalingam G, Perry M, Ward S, Brett S, Castello-Cortes A, Brunner M . Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med. 2006; 355(10):1018-28. DOI: 10.1056/NEJMoa063842. View

12.

Beatty G, Chiorean E, Fishman M, Saboury B, Teitelbaum U, Sun W . CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science. 2011; 331(6024):1612-6. PMC: 3406187. DOI: 10.1126/science.1198443. View

13.

Ngiow S, Young A, Blake S, Hill G, Yagita H, Teng M . Agonistic CD40 mAb-Driven IL12 Reverses Resistance to Anti-PD1 in a T-cell-Rich Tumor. Cancer Res. 2016; 76(21):6266-6277. DOI: 10.1158/0008-5472.CAN-16-2141. View

14.

Berghen N, Dekoster K, Marien E, Dabin J, Hillen A, Wouters J . Radiosafe micro-computed tomography for longitudinal evaluation of murine disease models. Sci Rep. 2019; 9(1):17598. PMC: 6879529. DOI: 10.1038/s41598-019-53876-x. View

15.

Bennett S, Carbone F, Karamalis F, Flavell R, Miller J, Heath W . Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature. 1998; 393(6684):478-80. DOI: 10.1038/30996. View

16.

Hughes R, Qian B, Rowan C, Muthana M, Keklikoglou I, Olson O . Perivascular M2 Macrophages Stimulate Tumor Relapse after Chemotherapy. Cancer Res. 2015; 75(17):3479-91. PMC: 5024531. DOI: 10.1158/0008-5472.CAN-14-3587. View

17.

Quezada S, Jarvinen L, Lind E, Noelle R . CD40/CD154 interactions at the interface of tolerance and immunity. Annu Rev Immunol. 2004; 22:307-28. DOI: 10.1146/annurev.immunol.22.012703.104533. View

18.

Garg A, Romano E, Rufo N, Agostinis P . Immunogenic versus tolerogenic phagocytosis during anticancer therapy: mechanisms and clinical translation. Cell Death Differ. 2016; 23(6):938-51. PMC: 4987738. DOI: 10.1038/cdd.2016.5. View

19.

Vonderheide R, Burg J, Mick R, Trosko J, Li D, Shaik M . Phase I study of the CD40 agonist antibody CP-870,893 combined with carboplatin and paclitaxel in patients with advanced solid tumors. Oncoimmunology. 2013; 2(1):e23033. PMC: 3583942. DOI: 10.4161/onci.23033. View

20.

van Kooten C, Banchereau J . CD40-CD40 ligand. J Leukoc Biol. 2000; 67(1):2-17. DOI: 10.1002/jlb.67.1.2. View